• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.

作者信息

Udwadia Zarir F, Barkate Hanmant, Patil Saiprasad, Rangwala Shabbir, Wu Wen, Caracta Cynthia F, Tandon Monika

机构信息

Breach Candy Hospital, Mumbai, India.

Glenmark Pharmaceuticals Limited, Mumbai, India.

出版信息

Int J Infect Dis. 2021 Apr;105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15.

DOI:10.1016/j.ijid.2021.02.028
PMID:33601032
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8012082/
Abstract
摘要

相似文献

1
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.对Udwadia等人发表的文章《口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻至中度COVID-19中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验》所收到评论的回复
Int J Infect Dis. 2021 Apr;105:686-687. doi: 10.1016/j.ijid.2021.02.028. Epub 2021 Feb 15.
2
Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.关于Udwadia等人所著的《口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻度至中度COVID-19中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验》致编辑的信
Int J Infect Dis. 2021 Apr;105:722. doi: 10.1016/j.ijid.2021.02.035. Epub 2021 Feb 15.
3
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.口服RNA依赖性RNA聚合酶抑制剂法匹拉韦在轻至中度新型冠状病毒肺炎中的疗效和安全性：一项随机、对照、开放标签、多中心3期临床试验
Int J Infect Dis. 2021 Feb;103:62-71. doi: 10.1016/j.ijid.2020.11.142. Epub 2020 Nov 16.
4
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
5
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.法匹拉韦治疗新型冠状病毒肺炎患者的临床疗效与安全性
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.12.005. Epub 2020 Dec 7.
6
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
7
Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.印度医护人员使用法匹拉韦治疗 COVID-19 的真实世界经验。
J Assoc Physicians India. 2022 Dec;69(12):11-12.
8
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.法匹拉韦与COVID-19早期门诊治疗的必要性
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.02489-20.
9
Comment on: Favipiravir, an antiviral for COVID-19?关于：法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？的评论
J Antimicrob Chemother. 2021 Jan 1;76(1):279-280. doi: 10.1093/jac/dkaa378.
10
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.关于《法匹拉韦治疗中重度新型冠状病毒肺炎的安全性和有效性》的评论
Int Immunopharmacol. 2022 Jan;102:107693. doi: 10.1016/j.intimp.2021.107693. Epub 2021 May 28.

引用本文的文献

1
ESCMID COVID-19 living guidelines: drug treatment and clinical management.ESCMID COVID-19 临床实践指南：药物治疗和临床管理。
Clin Microbiol Infect. 2022 Feb;28(2):222-238. doi: 10.1016/j.cmi.2021.11.007. Epub 2021 Nov 22.

本文引用的文献

1
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
2
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
3
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.用于流感的神经氨酸酶抑制剂：对监管和死亡率数据的系统评价与荟萃分析
Health Technol Assess. 2016 May;20(42):1-242. doi: 10.3310/hta20420.
4
Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.在考虑患者入组不均匀、失访、不依从和分层的情况下，对生存分析的样本量和检验效能进行评估。
Biometrics. 1986 Sep;42(3):507-19.